Grants per year
- 1 - 25 out of 71 results
Search results
-
Active
(OE) Prot #CNMAu8.EAP02: A Second Expanded Access Protocol for Amyotrophic Lateral Sclerosis with CNM-Au8
5/11/23 → 5/11/26
Project: Research project
-
HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) G to Master Protocol DNL343
Massachusetts General Hospital, Denali Therapeutics Inc.
3/23/23 → 12/4/24
Project: Research project
-
Longitudinal Biofluids Core
Ajroud-Driss, S. & Ajroud-Driss, S.
11/1/22 → 10/31/24
Project: Research project
-
Clinic-based Multicenter ALS Natural History Data Collection
Ajroud-Driss, S. & Ajroud-Driss, S.
University of Minnesota, Food and Drug Administration
9/20/22 → 8/31/26
Project: Research project
-
A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects with Amyotrophic Lateral Scle
ICON Clinical Research, LLC, Mitsubishi Tanabe Pharma America, Inc.
8/8/22 → 8/8/25
Project: Research project
-
Cure SMA Care Center Network and Clinical Data Registry
Families of Spinal Muscular Atrophy
6/1/22 → 12/31/23
Project: Research project
-
HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) E to Master Protocol TREHALOSE S-005
Massachusetts General Hospital, NexMed, Inc.
3/1/22 → 12/4/24
Project: Research project
-
Protocol Number: A35-004 - Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Julius Clinical Research B.V, Amylyx Pharmaceuticals, Inc.
1/12/22 → 1/12/25
Project: Research project
-
Prot #BASICHR0053: Evaluation of digital technologies for home-based assessment of ALS patients
Novartis Pharmaceuticals Corporation
8/3/21 → 12/6/24
Project: Research project
-
Prot# MT-1186-A02: A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
ICON Clinical Research, LLC, Mitsubishi Tanabe Pharma America, Inc.
3/16/21 → 3/16/24
Project: Research project
-
Prot# 233AS102: An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 M
Quintiles, Inc., Biogen MA Inc.
11/24/20 → 9/30/25
Project: Research project
-
HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) D to Master Protocol Pridopidine | Double-Blind Phase
Ajroud-Driss, S. & Ajroud-Driss, S.
Massachusetts General Hospital
11/20/20 → 12/31/23
Project: Research project
-
Oxidative Markers and Efficacy in ALS/MND Phenotypes Treated with Edaravone: Proof of Concept
Loma Linda University, Mitsubishi Tanabe Pharma America, Inc.
9/2/20 → 9/2/24
Project: Research project
-
HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) C to Master Protocol CNM-Au8 | Double-Blind Phase
Ajroud-Driss, S. & Ajroud-Driss, S.
Massachusetts General Hospital
3/23/20 → 12/31/23
Project: Research project